XML 37 R21.htm IDEA: XBRL DOCUMENT v3.24.3
Capital Stock and Stockholders' Deficit
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Capital Stock and Stockholders' Deficit
12.
Capital Stock and Stockholders’ Deficit
The Allurion certificate of incorporation authorizes the issuance of up to 100,000,000 shares of Allurion preferred stock. As of December 31, 2023, no shares of Allurion preferred stock were outstanding.
Legacy Allurion Preferred Equity
In connection with the Business Combination, the Legacy Allurion preferred stock was retroactively adjusted, converted into common stock at the Exchange Ratio, and reclassified to permanent equity as a result of the reverse recapitalization. As of December 31, 2023, there is no Legacy Allurion preferred stock authorized, issued, or outstanding. The following table summarizes details of Legacy Allurion Preferred Stock authorized, issued, and outstanding immediately prior to the Business Combination (in thousands, except share amounts):
 
    
Preferred Stock
Authorized (1)
     
Preferred Stock
Issued and
Outstanding
     
Carrying
Value
  
Series A Preferred Stock
      2,276,786        2,276,786      $ 1,542  
Series
A-1
Preferred Stock
      1,513,028        1,486,048        2,842  
Series B Preferred Stock
      2,298,929        2,245,515        5,253  
Series C Preferred Stock
      8,113,616        7,927,446        39,122  
Series
D-1
Preferred Stock
      1,684,565        842,283        9,614  
Series
D-2
Preferred Stock
      3,644,616        3,644,616        24,054  
Series
D-3
Preferred Stock
      1,498,348        1,498,348        14,789  
  
 
 
     
 
 
     
 
 
  
Total
      21,029,888        19,921,042      $ 97,216  
  
 
 
     
 
 
     
 
 
  
Voting Rights
The Legacy Allurion preferred stockholders voted as a single class together with holders of all other classes and series of stock of Legacy Allurion on all actions to be taken by the stockholders of the Company. The Legacy Allurion preferred stockholders were entitled to the number of votes equal to the number of shares of Legacy Allurion common stock into which the shares held by each holder were then convertible. The Legacy Allurion Series C Preferred Stockholders were entitled to elect two members of the Board of Directors, and the Legacy Allurion common stockholders were entitled to elect four members of the Board of Directors.
Dividend Rights
All Legacy Allurion preferred stock participated in dividends with Legacy Allurion common stock on an
as-converted
basis when declared by the Board of Directors. The Legacy Allurion preferred stockholders were entitled to receive dividends, when and if declared, on a pro rata pari passu basis according to the number of shares of Legacy Allurion common stock held by such holder. The Legacy Allurion Series D preferred stockholders were also entitled to a cumulative dividend that accrues at the rate of 6% per annum. The dividend accrued on a daily basis from and including the issuance date of such shares, whether or not declared. Through the date of the Business Combination, no dividends had been declared.
Liquidation Preference
In the event of any voluntary or involuntary liquidation, dissolution, or
winding-up
of Legacy Allurion, before any payment were to be made to the holders of common stock, the holders of shares of Legacy Allurion
preferred stock then outstanding were entitled to be paid out of the funds and assets available for distribution to Legacy Allurion’s stockholders, on a pari passu basis, an amount per share equal to (i) the Legacy Allurion Series A, Series
A-1,
Series B and Series C preferred stock, a per share liquidation preference equal to $1.092, $2.850, $3.563 and $4.935, respectively, plus any accruing dividends accrued but unpaid, whether or not declared and (ii) the Legacy Allurion Series
D-1,
Series
D-2,
and Series
D-3
preferred stock, a per share liquidation preference equal to $17.809, $9.338, and $15.137, respectively, plus any accruing dividends accrued but unpaid, whether or not declared provided, that, if Legacy Allurion achieved a revenue milestone of $65.0 million in a trailing twelve month period (the “Milestone”), then in lieu of the foregoing, the holders of the Legacy Allurion Series
D-1,
Series
D-2,
and Series
D-3
Preferred Stock were entitled to receive an amount per share equal to $11.8725, $6.2256 and $10.0916, respectively, plus any accruing dividends accrued but unpaid, whether or not declared (collectively, the “Preferred Stock Preference”). After payment of the Preferred Stock Preference, the funds and assets available for distribution to Legacy Allurion’s stockholders, if any, would be initially distributed on a pro rata basis to the holders of common stock in Legacy Allurion in proportion to the number of shares of common stock held at an amount per share equal to 150% of the Original Issue Price of the Legacy Allurion Series A Preferred Stock ($1.092), plus any dividends declared but unpaid thereon (the “First Catchup Amount”). Any remaining funds and assets available for distribution to Legacy Allurion stockholders, if any, after the First Catchup Amount would then be distributed on a pro rata basis to the holders of common stock and preferred stock in proportion to the number of shares of common stock or preferred stock held.
Conversion Rights
Each share of Legacy Allurion preferred stock was convertible at any time, at the option of the holder, into one share of Legacy Allurion common stock, based upon a per share conversion factor of each series’ applicable original issuance prices, adjustable for certain dilutive events. Conversion was mandatory upon the closing of an IPO or deSPAC transaction, or upon the election of the holders of a majority of the then-outstanding Legacy Allurion preferred stock.
Redemption
The holders of Legacy Allurion Series A, Series
A-1,
Series B, Series
D-1,
Series
D-2,
and Series
D-3
preferred stock were not entitled to any redemption rights, other than those under their liquidation rights discussed above. Upon the election of the holders of a majority of shares of the Legacy Allurion Series C preferred stock, up to 50% of the outstanding shares of Legacy Allurion Series C preferred stock were redeemable at a price equal to 1.5 times the original issuance price, plus all declared, but unpaid dividends thereon, on a pro rata basis in an equal semiannual portion, after January 17, 2022. The Legacy Allurion Series C contingent redemption upon a deemed liquidation event resulted in mezzanine equity classification (outside of permanent equity) on the Company’s consolidated balance sheet.
Common Equity
The Allurion certificate of incorporation authorizes the issuance of up to 1,000,000,000 shares of Allurion Common Stock. As of December 31, 2023 and 2022, 47,688,096 and 27,079,856 shares of common stock were outstanding, respectively, after retrospectively adjusting for the effect of the reverse recapitalization.
 
The number of shares of Common Stock that have been reserved for the potential conversion or exercise, as applicable, of the Company’s securities as of December 31, 2023, is as follows:
 
Outstanding options to purchase common stock
      3,886,038  
Restricted Stock Units
      643,635  
Warrants to purchase preferred stock (as converted to warrants to purchase common stock)
      138,857  
Warrants to purchase common stock
      264,801  
Public warrants to purchase common stock
      18,759,838  
Earn-Out
shares
      9,000,000  
  
 
 
  
Total
      32,693,169  
  
 
 
  
Warrants to Purchase Common Stock
In connection with the closing of the Business Combination, all outstanding warrants to purchase Legacy Allurion preferred stock and Legacy Allurion common stock were converted into Rollover Warrants to purchase Allurion Common Stock using the Exchange Ratio. As of December 31, 2023, there were 403,658 such Rollover Warrants outstanding to purchase Common Stock. Upon the closing of the Business Combination, certain Legacy Allurion preferred stock and Legacy Allurion common stock warrants that were converted into Rollover Warrants were determined to be equity classified.
 
December 31, 2023
  
Issuance Date
   
Remaining
Contractual Term
(in years)
     
Underlying Equity Instrument
   
Balance Sheet
Classification
     
Shares Issuable
Upon Exercise
of Warrant
     
Weighted
Average Exercise
Price
  
12/1/2014
      0.9     
Common stock
   
 
Equity
 
      44,272      $ 2.44  
3/30/2021
      7.2     
Common stock
   
 
Liability
 
      130,053        6.73  
9/15/2022
      8.7     
Common stock
   
 
Liability
 
      45,238        12.14  
6/4/2022
      8.4     
Common stock
   
 
Liability
 
      45,238        12.14  
1/17/2017
      3.0     
Common stock
   
 
Equity
 
      73,349        0.02  
8/3/2017
      3.6     
Common stock
   
 
Equity
 
      9,779        1.13  
9/8/2017
      3.7     
Common stock
   
 
Liability
 
      28,764        1.05  
6/19/2018
      4.5     
Common stock
   
 
Liability
 
      17,977        1.05  
6/25/2019
      5.5     
Common stock
   
 
Liability
 
      8,988        1.05  
           
 
 
     
              403,658     
           
 
 
     
December 31, 2022
  
Issuance Date
   
Remaining
Contractual Term
(in years)
     
Underlying Equity Instrument
   
Balance Sheet
Classification
     
Shares Issuable
Upon Exercise
of Warrant
     
Weighted
Average Exercise
Price
  
4/1/2013      0.2      Series
A-1
Preferred Stock		      Liability        16,557      $ 1.95  
12/1/2014      1.9      Series B Preferred Stock      Liability        60,768        2.44  
3/30/2021      8.2      Series C Preferred Stock      Liability        130,053        6.73  
9/15/2022      9.7      Series
D-1
Preferred Stock		      Liability        45,238        12.14  
6/4/2022      9.4      Series
D-1
Preferred Stock		      Liability        45,238        12.14  
1/17/2017      4.0      Common stock      Liability        73,349        0.02  
8/3/2017      4.6      Common stock      Liability        9,779        1.13  
9/8/2017      4.7      Common stock      Liability        28,764        1.05  
6/19/2018      5.5      Common stock      Liability        17,977        1.05  
6/25/2019      6.5      Common stock      Liability        8,988        1.05  
           
 
 
     
              436,711     
           
 
 
     
 
In Compute Health’s initial public offering, it sold units at a price of $10.00 per unit, which consisted of one share of Class A Common Stock, $0.0001 par value, of Compute Health (“Class A Common Stock”) and
one-half
of a redeemable warrant (each a “Public Warrant”) that entitled the holders the right to purchase one share of Class A Common Stock of CPUH at a price of $11.50 per share. On July 26, 2023, Compute Health’s Public Warrant holders approved an amendment (the “Warrant Amendment”) to the warrant agreement that governed all Compute Health’s Public Warrants. Per the terms of the Warrant Amendment, upon completion of the Business Combination, each of the outstanding Compute Health Public Warrants became exercisable for 1.420455 shares of the Company’s Common Stock, par value $0.0001 per share, at an exercise price of $8.10 per share and each Compute Health Public Warrant was exchanged for 0.6125 Allurion Public Warrants in the Business Combination. The Public Warrants will expire August 1, 2030, seven years after the completion of the Business Combination, or earlier upon redemption or liquidation.
The Company may redeem the outstanding Public Warrants for cash at a price of $0.01 per Public Warrant at any time commencing 90 days after the completion of the Business Combination, and provided that the last sales price of the Company’s Common Stock equals or exceeds $12.67 per share of any 20 trading days within a
30-day
trading period ending on the third trading day prior to the date on which notice of redemption is given.
The Company may redeem the outstanding Public Warrants for shares of our Common Stock at a price of $0.10 per Public Warrant at any time commencing 90 days after the completion of the Business Combination, and provided that the last sales price of the Company’s Common Stock equals or exceeds $7.04 per share of any 20 trading days within a
30-day
trading period ending on the third trading day prior to the date on which notice of redemption is given. Holders of the Public Warrants will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares based on the redemption date and the fair market value (the “Redemption Fair Market Value”) of the shares of the Company’s Common Stock. The Redemption Fair Market Value is determined based on the volume weighted average price of the Company’s Common Stock for the ten trading days immediately following the date on which notice of redemption is sent to the holders. As of December 31, 2023, the Company has not redeemed any of the outstanding Public Warrants. As of December 31, 2023, there were 13,206,922 outstanding Public Warrants exercisable for 18,759,838 shares of Allurion Common Stock.
Chardan Equity Facility
On December 18, 2023, we entered into a ChEF Purchase Agreement (the “Purchase Agreement”) and a Registration Rights Agreement (the “Registration Rights Agreement”), each with Chardan Capital Markets (“Chardan”) related to a “ChEF,” Chardan’s committed equity facility (the “Chardan Equity Facility”). Pursuant to the Purchase Agreement, the Company has the right from time to time at its option to sell to Chardan up to the lesser of (i) $100,000,000 in aggregate gross purchase price of newly issued shares of the Company’s Common Stock, and (ii) 9,482,468 shares of Common Stock, which number of shares is equal to 19.99% of the shares of the Common Stock outstanding immediately prior to the execution of the Purchase Agreement (the “Exchange Cap”). In consideration for Chardan’s entry into the Purchase Agreement, Allurion agreed to issue to Chardan 35,511 shares of Allurion Common Stock (the “Commitment Shares”). The Company recorded $0.1 million to additional
paid-in
capital and $0.1 million of expense in connection with the issuance of the Commitment Shares. The Company expensed an additional $0.1 million related to a
non-refundable
structuring fee (the “Structuring Fee”) immediately following commencement. As of December 31, 2023, the Company had not sold any shares of Common Stock to Chardan in connection with the Purchase Agreement.